Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology
9:30 am - Wednesday 4th February 2026
- Confronting the translational hurdles that limit liquid biopsy adoption in drug development, from tumor heterogeneity and assay sensitivity to cost and trial feasibility
- Integrating emerging technologies such as methylation profiling and AI with the rigor required for clinical validation in oncology trials
- Defining how pharma decision-making will shape the path from exploratory assays to scalable, routine tools that deliver real patient impact
